Human alpha-galactosidase variants
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
1. A method for treating Fabry disease in a subject, comprising administering to a subject having Fabry disease an effective amount of a recombinant alpha galactosidase A comprising an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 5, wherein said amino acid sequence comprises a substitution at position 206, wherein said position is numbered with reference to SEQ ID NO: 5, and wherein one or more symptoms of Fabry disease in the subject are ameliorated.
2. The method of claim 1 , wherein said treated subject is able to eat a diet that is less restricted in its fat content than diets required by subjects with Fabry disease.
3. The method of claim 1 , wherein said subject is an infant or a child.
4. The method of claim 1 , wherein said subject is an adult or a young adult.
5. The method of claim 1 , wherein the substitution at position 206 is 206A, 206M, 206Q, 206R, 206T, 206E, 206G or 206S.
6. The method of claim 1 , wherein the substitution at position 206 is 206A.
7. The method of claim 1 , wherein the recombinant alpha galactosidase A comprises an amino acid sequence comprising at least 96%, sequence identity to SEQ ID NO: 5.
8. The method of claim 1 , wherein the recombinant alpha galactosidase A comprises an amino acid sequence comprising at least 97%, sequence identity to SEQ ID NO: 5.
9. The method of claim 1 , wherein the recombinant alpha galactosidase A comprises an amino acid sequence comprising at least 98%, sequence identity to SEQ ID NO: 5.
10. The method of claim 1 , wherein the recombinant alpha galactosidase A comprises an amino acid sequence comprising at least 99%, sequence identity to SEQ ID NO: 5.